Kornimate/medical-research-clean huggingface dataset:
neuro-affective response to light in depressed adolescents and young adults

Conditions: Depression in Adolescence; Depression in Adults

Summary: the goal of this neuroimaging pilot study is to understand developmental differences in the impact of therapeutic wavelength light (blue light) versus a non-therapeutic wavelength (red light) on emotional brain function in depression. the main questions this study aims to answer are: * does acute exposure to blue light (vs red light) stabilize emotional brain function in depressed individuals? * are stabilizing effects of blue light (vs red light) stronger for blue light in adolescents than young adults? participants will complete: * a magnetic resonance imaging brain scan, in which we will examine the effect of blue versus red light on emotional brain function at rest and in response to rewards and losses. * a pupillometry test of sensitivity to blue vs red light * clinical interviews and surveys * screening measures for drug and alcohol use, mri safety, and current pregnancy \[if relevant\] * home sleep tracking with sleep diary and actigraphy for one week


Eligibility criteria:
inclusion criteria: * dsm-5 major depressive episode * (if \<18yr) parent or guardian can attend the baseline clinical interview exclusion criteria: * unable to read and write in english * intellectual disability. * left or mixed handedness * use of psychotropic medication other than stable selective serotonin reuptake inhibitor (ssri) medication (\> 2 months) * lifetime bipolar disorder or schizophrenia, or substance/alcohol disorder in the past 3 months. * factors influencing light and color sensitivity (i.e., color-blindness, serious ophthalmological conditions, photo-sensitizing medication). * factors influencing the ability to maintain a stable sleep schedule (i.e., shift work, severe sleep disorders, extremely late or early sleep schedule). * severe medical illness, neurological disorders, or history of head trauma. * current pregnancy or nursing * mri contraindication (e.g., metals in the body, recent tattoo, claustrophobia) * positive alcohol or substance use screen at mri visit
study to gather information on the kidney function of patients with non-valvular atrial fibrillation (irregularly heart beats which is not caused by a heart valve problem) treated with rivaroxaban or vitamin k antagonists

Conditions: Non-Valvular Atrial Fibrillation

Summary: by evaluating routine clinical practice data from the uk primary care database, researchers in this study want to gather information on the kidney function of patients with non-valvular atrial fibrillation (nvaf, irregularly heart beats which is not caused by a heart valve problem) who are treated with rivaroxaban (non-vitamin k antagonist, brand name xarelto) or vitamin k antagonists (vkas). the study planned to enroll about 25,000 male or female patients who were at least 18 years old and were new users of rivaroxaban or vkas between 01 january 2014 and 30 september 2019. researchers are especially interested in whether patients experienced under treatment any worsening in kidney function, the onset of acute kidney diseases or injuries. in addition, risk of worsening in kidney function in patients with or without diabetes or heart failures are of interest to the researchers.


Eligibility criteria:
inclusion criteria: * aged ≥18 years in the imrd-uk database * a first prescription for either rivaroxaban or a vka between 01 january 2014 and 31 march 2019. the date of the first rivaroxaban/vka prescription will be set as the start date (start of follow-up for that patient). the follow-up will be extended until 30 september 2019 to ensure that each patient has at least 6 months of potential follow-up. * a diagnosis of af recorded any time before start date or within 2 weeks after start date. * registered with their general practice at least 1 year before the start date and have a recorded prescription of any drug at least 1 year before the start date. * registered with a general practice with data considered to be up-to-standard quality. exclusion criteria: * a prescription for any oac before the start date - all first-time rivaroxaban/vka users will therefore be oac naïve * a record of heart valve replacement or mitral stenosis any time before the start date or in the 2 weeks after the start date. * a record of deep vein thrombosis, pulmonary embolism, or hip/knee surgery in the 3 months before the start date (because these are all alternative reasons for noac initiation). * a record of esrd (including renal transplant patients) on/before the start date
polydeoxyribonucleotide -placentex mastelli(pdrn) for the treatment of diabetic ulcers

Conditions: Diabetic Ulcer; Foot Ulcer Unhealed

Summary: the main objective of the study is to evaluate the efficacy of the polydeoxyribonucleotide in improving the healing of diabetic foot ulcers.

this trial will involve diabetic patients with foot ulcers who meet the inclusion/exclusion criteria. at least 200 patients aged 45-80yrs will be enrolled in the study and randomly allocated to receive the active drug or the placebo in indistinguishable formulations. after 2 months closure rate of the ulcer will be evaluated.

Eligibility criteria:
inclusion criteria: * male or female aged 45-80yrs * minimum schooling 5yrs * type i or ii diabetes since at least 5yrs with a stable metabolic control * foot ulcer since minimum 2 weeks * ulcer \>1cm and \<16cm at day 0 * ulcer grade 1 or 2 wagner scale * wound free of necrotic debris * tcpo2 \>29mmhg * not pregnant or lactant exclusion criteria: * non-consenting patient * history of alcohol or drug abuse * gangrene on any part of the affected foot * ongoing untreated infections * ulcer over a charcot deformity * use of a systemic cicatrizant drug in the past 10 days * malnutrition * neurological or psychiatric pathologies * liver or kidney insufficiency * corticosteroid or immunosuppressive or cytotoxic therapy * other severe pathologies * proven hypersensitivity to the drug or to any related component

Keywords: diabetes foot ulcer polydeoxyribonucleotide
intravenous versus intra-peritoneal dexamethasone on the incidence of postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: effect of intravenous versus intra-peritoneal dexamethasone on the incidence of postoperative nausea and vomiting following laparoscopic gynecological surgeries.


Eligibility criteria:
inclusion criteria: 1. adult female patients 2. american society of anesthesiologist class i \& ii 3. undergoing laparoscopic gynecological surgeries exclusion criteria: 1. patient refusal to participate in the study 2. patients with coagulopathy or under anticoagulation therapy. 3. infection near the site of needle insertion. 4. body mass index \> 40kg/m2 5. patients with any neurological or neuromuscular disorder or history of seizures. 6. known allergy to any drug used in the study.
amphotericin versus posaconazole for pulmonary mucormycosis

Conditions: Mucormycosis; Pulmonary (Etiology)

Summary: pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). surgery and antifungal therapy are central in the management of mucormycosis. unlike rhino-orbital mucormycosis, surgery is not feasible in several patients with pulmonary mucormycosis. hence, treatment is primarily with antifungal therapy. amphotericin b is the standard of care in the medical management of mucormycosis. however, amphotericin b is expensive, has significant adverse events, and is available only in parenteral formulation. posaconazole is effective against mucorales, and is currently approved for salvage therapy of mucormycosis. recent evidence suggest that in several patients, posaconazole may be effective as a monotherapy upfront. in the current study posaconazole versus amphotericin b will be evaluated for the management of pulmonary mucormycosis in a randomized clinical trial.


Eligibility criteria:
inclusion criteria: subjects with proven or probable pulmonary mucormycosis. participants with a suspicion of pulmonary mucormycosis (as defined previously) based on compatible clinical presentation and compatible imaging will be screened for inclusion in the study. exclusion criteria: * failure to provide informed consent * contraindications or hypersensitivity to amphotericin b, posaconazole or their components * already received \>4 days of antifungals prior to randomization into the study * pregnant women * high chances of mortality within 48 hours of enrolment into the study subjects with possible pulmonary mucormycosis will also be excluded, if their diagnosis is not confirmed within four working days of enrollment

Keywords: fungal pneumonia, zygomycosis invasive mold disease mucorales posaconazole
syntax study: taxus drug-eluting stent versus coronary artery bypass surgery for the treatment of narrowed arteries

Conditions: Coronary Artery Disease

Summary: the syntax trial is designed to determine the best treatment for patients with complex coronary disease (blocked or narrowed arteries in both the right and left sides of the heart) by randomizing patients to receive either percutaneous coronary intervention (pci) with polymer-based paclitaxel-eluting taxus stents or to coronary artery bypass surgery (cabg).

due to the introduction of drug-eluting stents (dess) and to improvements in therapy for both percutaneous coronary intervention (pci) and coronary artery bypass surgery (cabg) patients, pci is challenging cabg as the gold standard for treatment of three vessel (3vd) and left main (lm) coronary disease. syntax is a novel, randomized trial with nested registries comparing pci with paclitaxel-eluting taxus stents to cabg for 3vd and lm patients to evaluate the best treatment for these patients with complex coronary disease. patients at participating centers will be evaluated by both a cardiothoracic surgeon and by an interventional cardiologist. those patients who are determined to be eligible for treatment by both pci and cabg will be randomized to receive either pci with a polymer-based paclitaxel-eluting taxus stent or cabg. patients who are determined to be unsuitable for treatment by pci will be treated by cabg and will be entered into a cabg registry to help define the patient population in which stenting continues to be an unacceptable treatment option. similarly, patients who are determined to be unsuitable for treatment by cabg will be treated by pci, using any interventional techniques or devices with or without the use of des, and entered into a pci registry to help define the patients for whom cabg is considered inappropriate.

Eligibility criteria:
inclusion criteria: * three-vessel disease, left main disease or lm equivalent with or without 1, 2 or 3vd (left anterior descending \[lad\], left circumflex \[lcx\], right coronary artery \[rca\] territory) * de novo lesions with at least 50% stenosis * myocardial ischemia (stable, unstable, silent) exclusion criteria: * prior pci or cabg * acute myocardial infarction (with creatinine kinase \>2x upper limit of normal) * concomitant cardiac valve disease requiring surgical therapy (reconstruction or replacement) * participation or planned participation in another cardiovascular clinical study before 1 year follow-up is completed * inability to give informed consent due to mental condition, mental retardation, or language barrier

Keywords: three-vessel coronary artery disease left main coronary artery disease
oral health, bite force and dementia

Conditions: Dementia; Oral Hygiene; Chewing Problem

Summary: study aims: the primary aim is to identify influencing variables on oral hygiene / oral health and bite force in patients with dementia.


Eligibility criteria:
inclusion criteria: * \> 59 years * no acute processes being present * no known cranio-mandibular dysorder (cmd) or finding of any cmd during study participation * non or maximum of one dental hygiene treatment in the last 12 months exclusion criteria: * younger than 60 years * acute processes in the oral-facial region * known cdm case * more than one dental hygiene treatment in the last 12 months

Keywords: oral health bite force chewing efficiency dementia elderly aged
ethanol lock for the salvage of infected long-term vascular access

Conditions: Bacteremia

Summary: long-term venous devices (e.g.ports, tunneled catheters,...) may become infected. sometimes it is very difficult to treat the infection and it is necessary to remove the device. the purpose of this study is to determine the efficacy of instilled ethanol ("ethanol lock therapy") versus instilled antibiotics ("antibiotic lock therapy") to save long-term venous device when infected, preventing their removal.


Eligibility criteria:
inclusion criteria: * age: \>1 year and 10 kgs * long-term vascular device in place at least for 7 days * catheter-related infection (at least presumed) * will to save the infected device (expected high risk access) exclusion criteria: * known ethanol-allergy * known antabuse-like drugs in use * religious refusal * s.aureus or candida spp. as main pathogens (except in the unusual and documented scenarios when replacement of vascular access device proved to be very difficult) * tract or pocket infection * complicated infection (septic shock, infectious thrombosis, osteomyelitis, endocarditis)

Keywords: ethanol lock therapy vascular access central venous catheter sepsis
optimizing plyometric training for functional recovery post-acl reconstruction

Conditions: Anterior Cruciate Ligament Injury; Knee Injury

Summary: while surgical anterior cruciate ligament reconstruction (aclr) of the knee restores passive stability, studies are showing consistently poor long-term outcomes. unusually high risks of early-onset osteoarthritis and re-injury, and low rate of return to sport following aclr all seem to be related to a chronic tendency to land stiff-legged from a jump or hop, which itself may be due to fear of re-injury. decreased knee bending for force absorption simultaneously decreases performance level and increases risk for injury and arthritic changes. the purpose of the proposed study is to compare a current best-practice plyometric training program to one utilizing body weight support to increase repetition and improve performance in the initial phases. the investigators hypothesize that we will see larger improvements in absorptive capacity of the knee and better confidence in activity immediately following body weight support training, as well as improved retention of training effects after a two-month period.


Eligibility criteria:
inclusion criteria: * speak and understand english * age between 12-35 years * unilateral anterior cruciate ligament reconstruction between 6-48 months prior * activity level greater than or equal to level 5 on the tegner activity scale exclusion criteria: * weight in excess of 300 pounds (136 kg) * contralateral/bilateral acl reconstruction or an unreconstructed acl injury * history of a posterior cruciate ligament injury * lower extremity of back injury or other condition (e.g. cerebral palsy) that has limited their normal activities of daily living within the last 6 months

Keywords: knee plyometrics motor learning psychological factors
assessment of an automated telesurveillance system on serious falls prevention in an elderly suffering from dementia specialized care unit: the urcc

Conditions: Mentally Ill Old Subjects

Summary: 2 urcc in the limousin region will be equipped with the automated telesurveillance system. patient will be selected by ward's geriatrician and randomized into two groups after informed consent. one group will have cameras installed and the other will not and will act as a comparison group. patient will be assessed twice during the study, at admission in (inclusion visit) and at outcome from the urcc (end of study visit). each assessment implies a standard geriatric assessment, a fall questionnaire, a neuropsychiatric inventory for behavioral disturbances and a quality of life questionnaire (eq5d). every fall will be considered as adverse events and will therefore be listed along the study and characterized in types and number.


Eligibility criteria:
inclusion criteria: * patient aged more than 65 years old * patient admitted in limoges or brive's urcc * patient informed consent and/or proxy consent * patient covered by the french health insurance exclusion criteria: * patient without national health insurance coverage * patient with a short term prognosis pathology
rtms treatment of persistent headache and post concussion symptoms attributed to mild traumatic injury to the head

Conditions: Brain Injuries, Traumatic; Concussion, Brain; Headaches Chronic; Headache; Post-Traumatic Headache; Mild Traumatic Brain Injury; Transcranial Magnetic Stimulation

Summary: the objective of this study is to investigate the treatment effect of repetitive transcranial magnetic stimulation in patients with a history of both persistent post-traumatic headache and post-concussion symptoms. in this double-blind, sham-controlled, concealed allocation, randomized clinical trial, 20 patients aged 18-65 yrs will be recruited from the calgary brain injury program (cbip) and the calgary headache assessment and management program (champ) / calgary chronic pain centre, calgary, alberta, canada. patients will engage in a two-week rtms treatment protocol (10 treatments) and will be followed for 6 months after therapy.

demographic information will be collected two weeks prior to starting the study including age, sex, education, headache history, concussion history, past medical history, medication use, and family medical history. headache history will be collected including frequency, severity, medication-use, type of headache, associated symptoms (i.e. neck pain, photophobia, phonophobia, nausea, vomiting) and headache triggers. baseline questionnaires will be completed including headache intensity scale - 6 (hit-6), rivermead ppcs questionnaire, british columbia post-concussion symptom inventory (bc-psi), montreal cognitive assessment (moca), quality of life after brain injury questionnaire (qolibri), patient health questionnaire-9 (phq-9), generalized anxiety disorder scale-7 (gads-7) and the post traumatic stress disorder checklist for dsm-5 (pcl-5). patients will keep a two-week baseline headache diary before treatment, 2 weeks during treatment, 2 weeks following rtms, and for 2 weeks at the 1, 3, and 6 month follow up assessments (total of 12 weeks). patients will be reassessed at the completion of their rtms treatment (day 14), and at 1, 3, and 6 months post-treatment. the questionnaires including: hit-6, rivermead ppcs questionnaire, pc-psi, qolibri, phq-9 and gad-7 will be completed at all follow up visits.

Eligibility criteria:
inclusion criteria: * diagnosis of a persistent headache attributed to traumatic injury to the head based on the ichd-3 criteria * diagnosis of persistent post-concussion symptoms based on the icd-10 criteria * mtbi occurrence from 3 months to 5 years from study start date exclusion criteria: * prior history of tms therapy * tms-related contraindications (pacemaker, metallic implant) * history of chronic headache (\>15 days/month for 3 months) or migraine prior to most recent trauma * other medical conditions such as: structural brain disease, previous seizure, psychotic disorders (schizophrenia, bipolar disorder), liver or kidney disease, malignancy, uncontrolled hypertension or diabetes, and pregnancy
to evaluate the safety and efficacy of lithovue ureteroscope system in chinese patients with urinary disease

Conditions: Urinary Tract Disease

Summary: to evaluate the safety and efficacy of lithovue ureteroscope system in chinese population.

this is a prospective, multicenter, single-arm, pre-market study.the aim of this study is to evaluate the safety and efficacy of lithovue ureteroscope system in chinese population, to support the regulatory approval by cfda. the study will enroll 60 patients in 3 investigational sites in china. the primary endpoint is procedure success rate of lithovue ureteroscope system, the procedure success is defined as:scope condition is suitable to complete the procedure and not requiring immediate scope substitution; it is also considered as a procedure success if the clinical effect is the same as that from the lithovue scope per investigator's judgement in the case of a scope change (non-lithovue).

Eligibility criteria:
inclusion criteria: 1. willing and able to provide written informed consent to participate in the study 2. willing and able to comply with the study procedures 3. diagnosed as urinary disease and indicated for flexible ureteroscope procedure 4. for stone cases, the diameter of stones is less than or equal to 2cm in order to avoid staged procedures exclusion criteria: 1. surgeries are contraindicated 2. flexible ureterocope procedure is contraindicated 3. based on doctor's evaluation, the patient's medical condition doesn't fit for this study 4. for stone cases, the diameter of stones is greater than 2cm 5. women of childbearing potential who are or might be pregnant at the time of this study
study of methotrexate efficacy versus cyclosporine in moderate to severe atopic dermatitis patients

Conditions: Atopic Dermatitis

Summary: the systemic treatments for moderate to severe atopic dermatitis (ad) are limited to phototherapy and cyclosporine with the risks respectively of either carcinoma, or hypertension or nephropathy. methotrexate was effective in 75% of moderate to severe ad patients with good tolerance in an open retrospective study. we want to confirm our observations: a non inferiority multicenter clinical trial, methotrexate versus cyclosporine, will be conducted in 100 patients for 24 weeks.


Eligibility criteria:
inclusion criteria: * patients aged \> 18 years old. * both genders eligible for study. * moderate to severe ad. * scorad \> 15. * participants must use a contraceptive method during the trial and for 3 months after the end of the trial for female and 5 months for male participants. * participants must be able to understand and sign the informed consent, and comply with all aspects of the protocol. * patients must be registered in a social security system or with a health insurance coverage. exclusion criteria: * pregnant or lactating women. * evolutive skin disease. * patients with a clinically significant disease (chronic, recurrent or active). * systemic corticotherapy or immunosuppressive treatment during the previous month, or local corticoid the week before the inclusion. * contra-indication to methotrexate and cyclosporine. * exposure to phototherapy: cumulative dose \> 2000 j/cm2. * patients deprived of their civic rights, in custody, or subject to a tutorial, judiciary or administrative decision. * patients under a protection measure. * patients in a critical medical situation. * patients with a personal situation evaluated by the investigator as unable to give optimal participation to the study, or where the study could constitute a risk for the patient.

Keywords: atopic-dermatitis scorad methotrexate ciclosporin